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BACKGROUND: Metabolites released by the gut microbiota may influence host metabolism and immunity. We have tested the
hypothesis that inulin-type fructans (ITF), by promoting microbial production of short-chain fatty acids (SCFA), influence cancer cell
proliferation outside the gut.
METHODS: Mice transplanted with Bcr-Abl-transfected BaF3 cells, received ITF in their drinking water. Gut microbiota was analysed by
16S rDNA polymerase chain reaction (PCR)–denaturing gradient gel electrophoresis (DGGE) and qPCR. Serum Short-chain fatty
acids were quantified by UHPLC-MS. Cell proliferation was evaluated in vivo, by molecular biology and histology, and in vitro.
RESULTS: Inulin-type fructans treatment reduces hepatic BaF3 cell infiltration, lessens inflammation and increases portal propionate
concentration. In vitro, propionate reduces BaF3 cell growth through a cAMP level-dependent pathway. Furthermore, the activation of
free fatty acid receptor 2 (FFA2), a Gi/Gq-protein-coupled receptor also known as GPR43 and that binds propionate, lessens the
proliferation of BaF3 and other human cancer cell lines.
CONCLUSION: We show for the first time that the fermentation of nutrients such as ITF into propionate can counteract malignant cell
proliferation in the liver tissue. Our results support the interest of FFA2 activation as a new strategy for cancer therapeutics. This
study highlights the importance of research focusing on gut microbes–host interactions for managing systemic and severe diseases
such as leukaemia.
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The gut microbiota profits from its high metabolic potential for
generating its own energy, mainly by fermenting dietary non-
digestible carbohydrates (Neish, 2009). The carbohydrate fermen-
tation end products are gases and organic acids, including lactate
and short-chain fatty acids (SCFA) such as acetate, propionate and
butyrate (Neish, 2009). In humans, butyrate constitutes a major
energy source for colonocytes (Guarner and Malagelada, 2003).
Propionate is mainly taken up by the liver, whereas acetate reaches
peripheral tissues (Guarner and Malagelada, 2003). Short-chain
fatty acids are considered key metabolic and immune cell
regulators (Neish, 2009). Acetate and propionate exhibit anti-
inflammatory properties in human monocytes and in vivo in colitis
models (Cox et al, 2009; Maslowski et al, 2009). In human cancer
cells, butyrate and other SCFA affect the cell cycle by inhibiting
proliferation and inducing differentiation and cell death
(Siavoshian et al, 2000; Aoyama et al, 2010; Tang et al, 2011a).
Intracellular mechanisms involved in cell proliferation and cell
death (activation of caspases 3 and 7, and decreased histone
deacetylase activity), have been extensively evaluated using in vitro
assays (Aoyama et al, 2010; Tang et al, 2011a). More recently, two
G-protein-coupled receptors, free fatty acid receptor 3 (FFA3) and
FFA2, also known as GPR41 and GPR43, respectively, have been
identified as receptors for SCFA (Brown et al, 2003; Le Poul et al,
2003). Propionate is considered the most potent endogenous
agonist for both FFA3 and FFA2 (Brown et al, 2003; Le Poul et al,
2003). Free fatty acid receptor 2 expression occurs mainly in
immune cells, but also in adipocytes, enterocytes and endocrine
cells (Brown et al, 2003; Le Poul et al, 2003). Free fatty acid
receptor 3 exhibits a widespread expression pattern (spleen, lymph
nodes, bone marrow, adipose tissue and colon) (Brown et al, 2003;
Le Poul et al, 2003). Lessons from FFA2 knock-out mice and small-
interfering RNA technology, revealed properties of propionate and
acetate attributed to their FFA2-binding activity, for example, the
resolution of the inflammatory response in a mouse model of
colitis (Maslowski et al, 2009), neutrophil chemotaxis (Vinolo et al,
2011), glucagon-like peptide-1 secretion (Tolhurst et al, 2012) and
pre-adipocyte differentiation (Hong et al, 2005).
Based on the theory that butyrate decreases proliferation and
increases apoptosis of colon cancer cell lines (Siavoshian et al,
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2000; Tang et al, 2011a), a nutritional approach, that is,
administering fermentable non-digestible carbohydrates, has been
proposed as an adjuvant in the treatment of colon cancer (Pool-
Zobel and Sauer, 2007). Interestingly, fermentable non-digestible
carbohydrates might also be relevant to controlling tumour growth
outside the gastrointestinal tract. We, and others, have described
an oral administration of inulin-type fructans (ITF), which are
non-digestible carbohydrates, that decreases the tumour size in
liver or mammary cancer mouse models (Taper et al, 1997;
Kondegowda et al, 2011). Inulin-type fructans are fermented by
saccharolytic bacteria, leading to an increased production of SCFA
in the mouse caecum (Busserolles et al, 2003). As a prebiotic
nutrient, ITF change the composition and the activity of the gut
microbiota (Everard et al, 2011), and control the host metabolism
and immunity (primarily demonstrated in colitis, obesity and
diabetes models) (Cherbut et al, 2003; Cani et al, 2006; Cani et al,
2007). Even so, no mechanistic study investigating ITF systemic
anti-tumour effects has been performed so far.
We hypothesised that the increased SCFA production following
ITF administration could hinder systemic cancer progression, and
this could occur through FFA2 activation. We chose, as a model,
murine proB BaF3 cells that ectopically express Bcr-Abl because
they can invade and proliferate in the lymphoid organs (Ren, 2005;
Fiskus et al, 2006; Bindels et al, 2012), such as liver tissue, which
actively takes up the SCFA that originates from the gut. Here, we
demonstrate in vivo that ITF reduces BaF3 cell proliferation,
increases propionate in the portal vein and lowers systemic
inflammation, and in vitro that propionate reduces BaF3 cell
proliferation through a cAMP level-dependent pathway and that
FFA2 activation alters BaF3 cell growth.
MATERIALS AND METHODS
Animals
Female BALB/c mice (5-week-old, Charles River, France) were
housed with two mice per cage in a 12-h light/dark cycle. Either a
saline solution or BaF3 cells (1 106 cells in 0.1ml saline) were
injected into the tail vein of the anaesthetised mice. A day after the
BaF3 inoculation, half of the mice that were transplanted with BaF3
cells received 0.2 g per day of ITF (Orafti p95, Beneo-Orafti, Oreye,
Belgium) in the drinking water. The intake of food and water was
recorded every 2 days to monitor the ITF consumption. The mice
were killed at an advanced stage of the illness (13 days after the
BaF3 inoculation) after anaesthesia with ketamine/xylazine i.p.,
100 and 10mg/kg, respectively. Blood samples, liver, spleen and
caecum content were harvested for further analysis. The experi-
ment was approved by the local ethics committee, and the housing
conditions were as specified by the Belgian Law of 6 April 2010, on
the protection of laboratory animals (Agreement LA 1230314).
Tissue and cells mRNA analyses
Total RNA was isolated from the tissues and the cells using a
TriPure Isolation Reagent Kit (Roche Diagnostics, Penzberg,
Germany). Complementary DNA was prepared by reverse
transcription of 1 mg total RNA using a Reverse Transcription
System Kit (Promega, Madison, WI, USA). Quantitative polymer-
ase chain reactions (qPCR) were performed as previously
described (Bindels et al, 2012). The primer sequences for the
targeted genes are detailed in Supplementary Table 1.
Gut microbiota analyses
The gut microbiota composition was assessed by 16S rRNA gene
analysis using denaturing gradient gel electrophoresis (DGGE) and
qPCR, as previously described (Bindels et al, 2012). Genomic DNA
was extracted from the caecal content using a QIAamp DNA
Stool Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Full protocols are available online as
Supplementary Methods.
Biochemical and histological analyses
The plasma L-lactate concentration was determined spectro-
photometrically by measuring at 340 nm the increase of the
NADH-mediated absorbance in the presence of NADþ and
L-lactate dehydrogenase (Roche, Mannheim, Germany) in a basic
buffer. A spectrophotometric kit was used to determine the lactate
dehydrogenase activity (Diasys, Sopachem, Brussels, Belgium).
Plasma cytokines were measured using a customised multiplex kit
(Bio-Rad, Nazareth, Belgium) and Luminex technology (Bio-Plex,
Bio-Rad). The hepatic triglyceride content was determined using a
spectrophotometric kit (Diasys) after lipid extraction with
chloroform–methanol (2 : 1) according to Folch’s method. To
measure the hepatic glycogen content, liver tissue was digested in
an alkaline medium and, after neutralisation, incubated in the
absence or presence of amyloglucosidase. The glucose concentra-
tions were determined for each condition with a spectrophoto-
metric kit (Diasys), and the glycogen content was calculated as the
difference in the glucose concentrations plotted to a standard
curve. For the histological analysis, the formalin-conserved liver
was embedded in paraffin.
Short-chain fatty acids analysis
Short-chain fatty acids were quantified using ultraperformance
liquid chromatography coupled to mass spectrometry (UHPLC-MS)
following extraction from serum and subsequent derivatisa-
tion. The extraction and derivatisation protocols were performed
as described previously for valproic acid (Alric et al, 1981). Briefly,
SCFA were extracted from 50 ml of the portal serum with HCl,
acetonitrile and KCl. After centrifugation, the upper phase was
incubated with potassium carbonate. The derivatisation was
performed with 2-bromo-2-acetonaphthone in the presence of
1,4,7,10,13-pentaoxacyclopentadecane and K2CO3. At the end of
the reaction, the liquid phase was recovered and dried under a
nitrogen stream. The resulting residue was dissolved in methanol.
A 5-ml aliquot was analysed by UHPLC-MS using an LTQ-Orbitrap
Mass Spectrometer (ThermoFisher Scientific, Aalst, Belgium)
coupled to an Accela UHPLC System (ThermoFisher Scientific).
Analyte separation was achieved using a Hypersil Gold aQ
(50 2.1) column (Thermo Scientific). The mobile phases A and
B were composed of acetonitrile–H2O–acetic acid 10 : 90 : 0.1 (v/v/
v) and acetonitrile-acetic acid 100 : 0.1 (v/v), respectively. The
gradient (0.5mlmin 1) was designed as follows: 8min of 90% A; a
transition from 90% A to 100% B linearly over 6min; followed by
3min at 100% B and a subsequent re-equilibration at 90% A. We
performed MS analysis in the positive mode with an APCI
ionisation source. Acetate, propionate and butyrate were quanti-
fied using valproate as an internal standard, and the calibration
curves were prepared from pure standards diluted in water. The
nature of the analytes was confirmed by their exact mass, MS2
fragmentation and co-elution with pure standards. Additionally, to
reduce the acetate contamination, UltraPure Water (Cayman
Chemical, Tallinn, Estonia) and HPLC-grade acetonitrile (VWR,
Leuven, Belgium) were purified by SPE on StratoSpheres columns
(PL-HCO3 MP-resin, Varian, Agilent Technologies, Santa Clara,
CA, USA).
Cell culture and chemicals
The BaF3 cell line transfected with Bcr-Abl was a gift from Dr
K Bhalla (MCG Cancer Centre, Medical College of Georgia,
Augusta, GA, USA). The BaF3 cells were maintained in RPMI
medium 1640 supplemented with 10% foetal bovine serum (PAA
Gut microbiota, propionate and cancer cell growth
LB Bindels et al
1338
British Journal of Cancer (2012) 107(8), 1337 – 1344 & 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
clone, PAA, Pasching, Austria), streptomycin 100mgml 1, peni-
cillin 100 IUml 1 and 1% of non-essential amino acids solution
(Gibco, Inchinnan, Scotland) at 37 1C in humidified 5% CO2. The
generation of these cells is described in detail elsewhere (Fiskus
et al, 2006). The human histiocytic lymphoma U937 (Sundstrom
and Nilsson, 1976) and lymphoblast K562 cells were maintained in
the same conditions, except for the non-essential amino acids
solution.
All chemicals were purchased from Sigma-Aldrich, Saint Louis,
MO, USA, except the synthetic FFA2 agonist (4-chloro-a-(1-methyl
ethyl)-N-2-thiazolyl-benzeneacetamide) (CMTB) (Wang et al,
2010) (Ambinter, Paris, France).
Cell proliferation (MTT, manual counting, BrdU)
The cell growth assay is based on metabolically active cells cleaving
yellow thiazolyl blue tetrazolium bromide (MTT) to form purple
formazan crystals. The formazan absorbance was measured at
570nm, from which a background value, measured at 650 nm, was
subtracted. Cell proliferation is expressed as a percentage of the
value obtained for cells incubated with the vehicle (medium, PBS or
DMSO, final concentration between 0.1 and 0.2%). For manual
counting, intact cells (determined by exclusion of erythrosine) were
counted under a microscope in a Bu¨rker cell. The bromodeoxyur-
idine incorporation assay was performed following the manufac-
turer’s instructions (Cell Proliferation ELISA, BrdU colorimetric,
Roche, Mannheim, Germany). All of the assays were performed in
medium containing 10% foetal bovine serum. Complete protocols
are available online as Supplementary Methods.
Statistical analysis
The results are expressed as the mean±s.e.m. Student’s t-test, one-
way ANOVA with Tukey post hoc test and two-way ANOVA with
Bonferroni post hoc test were used for statistical analysis. Po0.05
was considered statistically significant (Graph-Pad Prism Software,
San Diego, CA, USA).
RESULTS
Inulin-type fructans administration decreases hepatic
infiltration of BaF3 cells and systemic inflammation in
mice
BaF3 cells were transplanted into mice resulting in an aggressive
malignancy that mimicked acute leukaemia and was characterised
by an accumulation of BaF3 cells in the liver and spleen. The liver
and spleen weights increased in the mice transplanted with BaF3
cells (BaF3 mice), in accordance with the fact that BaF3 cells
infiltrate these organs (Figure 1A). Intriguingly, ITF administra-
tion impaired the liver weight gain induced by BaF3 cells without
any significant effect on the spleen weight. Because Bcr-Abl is a
chimeric protein, solely and constitutively expressed in BaF3 cells,
it is a valuable marker of BaF3 cell presence. The reduced hepatic
expression of Bcr-Abl in BaF3-ITF mice compared with BaF3 mice
reflects a lower infiltration of the hepatic parenchyma by the BaF3
cells (Figure 1B) as suggested by histological observation
(Supplementary Figure 1A). Hepatic glycogen and triglyceride
contents cannot account for the difference in liver weight because
they were similar between BaF3 and BaF3-ITF mice
(Supplementary Figures 1B and C). Concordantly to the spleen
weight, splenic Bcr-Abl expression was not significantly modified
by ITF administration (Figure 1B, P¼ 0.21). The glycolysis
pathway becomes predominant in malignant cell lines and
tumours and generates lactacte as an end product, whereas lactate
dehydrogenase activity in the blood reflects a general cellular
turnover and is a negative prognostic factor of leukaemia
progression (Montillo et al, 2005; Sonveaux et al, 2008).
Accordingly, plasma L-lactate and plasma lactate dehydrogenase
activity were both increased in the presence of the BaF3 tumour,
whereas ITF administration decreased these levels (Figure 1C and D).
Of note, there were no changes in water or food intake due to the
ITF administration (data not shown).
Given that both cancer cell progression and ITF treatment are
able to modulate immunity, we measured a panel of cytokines in
the plasma. Plasma interleukin 4 (IL-4), interleukin 6 (IL-6),
interleukin 10 (IL-10), granulocyte colony-stimulating factor
(G-CSF), interleukin 8 (IL-8), monocyte chemo-attractant protein
1 (MCP-1) and RANTES were significantly increased in the BaF3
mice (Figure 1E–K). Inulin-type fructans administration to BaF3
mice decreased IL-4, IL-8 and MCP-1 levels (Figure 1E, I, J) with
no significant effect on IL-10, G-CSF and RANTES levels
(Figure 1G, H, K). Interleukin 6 is decreased by ITF treatment,
and this is significant by Student’s t-test (P¼ 0.04). Interferon
gamma (IFNg) tends to be decreased by ITF feeding (P¼ 0.05,
Student’s t-test) (Figure 1L).
Inulin-type fructans administration modifies gut
microbiota composition and increases propionate in the
portal vein
We hypothesised that ITF administration reduced BaF3 cell
infiltration and lowered systemic inflammation through gut
microbiota modulation. The changes in the gut microbial
composition were assessed using DGGE and qPCR of the 16S
rRNA gene sequences for total bacteria, Lactobacillus spp.,
Bifidobacterium spp. (two Gram-positive genera known for anti-
inflammatory properties (Louis et al, 2007)) and Bacteroides spp.
(a predominant Gram-negative genus). The DGGE fingerprints for
total bacteria revealed three separate clusters, corresponding to
each treatment (Figure 2A). The dendrogram of the DGGE
fingerprints showed that the BaF3-ITF mouse fingerprints are
closer to those from the control mice compared with the BaF3
mouse fingerprints. Total bacteria and the Gram-negative Bacter-
oides were modified by neither the BaF3 transplantation nor the
ITF administration (Figure 2B). Lactobacilli levels were reduced in
the BaF3 mice vs the control mice without any impact from the ITF
supplementation. Notably, the number of bifidobacteria was below
the quantification limit in the mice strain used in this study, that
is, BALB/c mice.
The caecal content weight tended to decrease in BaF3 mice (not
significant in one-way ANOVA, but P¼ 0.003 by Student’s t-test)
(Figure 2C). We can reasonably suggest that the decreased caecal
content weight in BaF3 mice results from the reduced food intake
observed during the last 2 days of the experiment (food intake from
day 11 to day 13: CT: 9.62±0.51; BaF3: 7.02±0.37g*; BaF3-ITF:
7.07±0.31g*; n¼ 4, *Po0.05 vs CT). However, the caecal content
weight was increased in BaF3-ITF mice, even if these mice ate the
same amount of food than BaF3 mice. This increase in the caecal
content weight reflects the fermentation that occurs upon ITF
feeding. The fermentation hypothesis is also supported by the
increased caecal tissue weight, only observed in BaF3-ITF mice
(Figure 2C). Because we hypothesised that increased SCFA levels
could explain the effect of the ITF treatment on cancer progression,
we set up a method to quantify the levels of acetate, propionate and
butyrate in the portal serum. BaF3 mice tend to exhibit a decreased
level of serum propionate and butyrate (P¼ 0.02 and 0.05,
respectively, Student’s t-test). The ITF supplementation did not
modify the acetate and butyrate levels, but did induce a two-fold
increase of propionate levels (Figure 2D–F).
Short-chain fatty acids decrease BaF3 cell proliferation
in vitro
As typical metabolites of ITF fermentation, SCFA are potentially
suitable candidates that could account for the effects of ITF on
Gut microbiota, propionate and cancer cell growth
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Figure 1 Inulin-type fructans treatment decreases the hepatic infiltration of the BaF3 cells and systemic inflammation in mice. (A) Liver and spleen weights
of the control mice (CT), mice transplanted with BaF3 cells (BaF3) and mice transplanted with BaF3 cells and fed ITF (BaF3-ITF). (B) Bcr-Abl mRNA levels,
ND: not detected. (C, D) Plasma L-lactate and lactate dehydrogenase (LDH) activity. (E–L) Plasma levels of IL-4, IL-6, IL-10, G-CSF, IL-8, MCP-1, RANTES
and IFNg. n¼ 7–8. *Po0.05 vs CT, yPo0.05 vs BaF3.
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BaF3 cell growth. Indeed, BaF3 cells incubation in the presence of
SCFA resulted in a time- and dose-dependent decrease in cell
proliferation, as shown by a MTT assay (Figure 3A–C). Notably,
SCFA at 10mM did not modify the pH of the medium. Amongst the
SCFA, acetate was less potent than propionate or butyrate. 0.2mM
propionate slightly but significantly reduced BaF3 cell growth
(after 48 h of incubation, control: 100±1%; propionate 0,2mM:
95±1% of control proliferation; n¼ 3 in triplicate, P¼ 0.0032).
Given that in vivo ITF increased propionate (but not acetate or
butyrate) and reduced BaF3 cell proliferation, we focused our
in vitro studies on the anti-proliferative effect of propionate.
Shorter-term incubations, and, therefore, supra-physiological
doses, were used to study the potential mechanisms of propionate.
BrdU incorporation, reflecting the DNA synthesis, was decreased
after 8 and 24 h of incubation in the presence of 2 and 10mM
propionate (Figure 3D). These results were confirmed by counting
living BaF3 cells incubated in the presence of 2mM propionate for
24, 48 or 72 h (Figure 3E).
Propionate reduces BaF3 cell growth through a cAMP
level-dependent pathway
Propionate is one of the most potent endogenous FFA2 ligands and
FFA2 is highly expressed by BaF3 cells (Maslowski et al, 2009).
Therefore, we next wanted to determine if a G-protein-coupled
receptor pathway (potentially FFA2) was involved in the anti-
proliferative effect of propionate. FFA2 displays a dual coupling
through Gi and Gq protein families (Brown et al, 2003; Le Poul
et al, 2003). Therefore, BaF3 cells were incubated with U73122, a
phospholipase C (PLC) inhibitor. PLC blockade did not blunt the
propionate-induced cell growth arrest (Figure 3F; raw data in
Supplementary Figure 2). Gi protein inhibits adenylyl cyclase and
subsequently reduces cAMP. Therefore, we next investigated if
cAMP levels have a role in the anti-proliferative effect of
propionate. DibutyrylcAMP, a cAMP analogue, or 3-isobutyl-1-
methylxanthine (IBMX), an inhibitor of phosphodiesterases,
slightly reduced the anti-proliferative action of propionate
(Figure 3F; raw data in Supplementary Figure 2). Furthermore,
isoproterenol, a b-adrenoceptor agonist that, among other proper-
ties, increases cAMP, also slightly reduced the anti-proliferative
effect of propionate (Supplementary Figure 2). Overall, these data
suggest that the anti-proliferative effect of propionate is partially
dependent on the cAMP level.
Free fatty acid receptor 2 activation decreases mouse and
human cell proliferation in vitro
Finally, we wanted to know whether FFA2 activation is actually
able to reduce BaF3 cell growth. To this end, we used CMTB, a
potent synthetic FFA2 agonist (Wang et al, 2010), and found that it
reduced cell proliferation in a time- and dose-dependent manner
(MTT and BrdU assays) (Figure 4A and B). These results were
confirmed by microscopic observation after the CMTB treatment
(Figure 4C). Furthermore, U73122, dibutyrylcAMP, IBMX and
isoproterenol inhibited CMTB-induced cell growth arrest, suggest-
ing that both cAMP- and PLC-dependent pathways are involved in
the anti-proliferative effect of CMTB (Supplementary Figure 3).
To support the role of FFA2 in CMTB and propionate effects, we
tested their impact on Lewis lung carcinoma (LLC) cells, a cell line
that expressed low levels of FFA2 (Supplementary Figure 4A). BaF3
cells were more sensitive to the anti-proliferative action of CMTB
and propionate than LLC cells that were almost completely
resistant to both treatments, after a 24-h incubation
(Supplementary Figure 4B and C). Remarkably, LLC and BaF3
cells were similarly sensitive to doxorubicin, a classical chemother-
apeutic agent (Supplementary Figure 4D) (Bray et al, 2010). We
can thus reject the hypothesis that LLC cells are generally resistant
to any kind of anti-proliferative treatment.
To further extend the concept of FFA2 as a new cancer
therapeutic target, we studied the effect of CMTB on two human
cancer cell lines, U937 cells and K562 cells. CMTB reduced the
growth of both cell lines. The U937 cells, which express a 25-fold
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Figure 3 Short-chain fatty acids decrease BaF3 cell proliferation in vitro. (A–C) BaF3 cells were incubated in the absence or presence of acetate,
propionate, butyrate for 24, 48 and 72 h before performing the MTT assay. (D) BrdU incorporation after 8 or 24 h incubation in the absence or presence of
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propionate for 24 h. Data are expressed as a percentage of the control performed for each pharmacological condition in the absence of propionate. MTT
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higher level of the FFA2 transcript as compared with the K562
cells, are more sensitive to CMTB treatment (Figure 4D and E).
DISCUSSION
In this study, we demonstrate in an acute leukaemia mouse model
that dietary ITF administration reduces cancer cell infiltration into
the liver and reduces the inflammation associated with cancer
progression. In vitro, we demonstrated that the anti-proliferative
effect of propionate was partially cAMP level-dependent, and that
FFA2 activation altered cancer cell proliferation. These results
support the idea of a role for gut microbiota in the control of
systemic cancer.
The anti-inflammatory effect of dietary ITF was demonstrated in
pathological conditions, such as obesity, diabetes or intestinal
inflammation (Cherbut et al, 2003; Cani et al, 2006; Cani et al,
2007) and this effect was related to the microbial changes induced
by ITF feeding, namely to an increase in bifidobacteria and
lactobacilli (Louis et al, 2007). The ITF fermentation, reflected by
the increased caecal content and tissue weights in BaF3-ITF mice,
is accompanied by changes in the total gut microbiota composi-
tion, without changing lactobacilli and bifidobacteria levels.
Therefore, at this stage, we cannot attribute the anti-inflammatory
effect of ITF to the changes in the level of lactic acid bacteria, as
suggested in other models.
The gut microbiota could influence BaF3 cell progression by
changing its metabolome. We hypothesised that a gut microbiota-
derived metabolite, that is increased upon ITF treatment and
specifically targets liver tissue, could mediate a protective effect.
Propionate fulfills all of these requirements because it is increased
in the portal vein of ITF-fed rats (Daubioul et al, 2002) and is
mostly taken up by the liver (Guarner and Malagelada, 2003). In
the present in vivo study, propionate levels were increased in the
portal blood of the BaF3-ITF mice. Of note, propionate and
butyrate levels tended to be decreased upon cancer. This could be
explained by the altered gut microbiota composition or by the
decreased food intake observed at the end of the treatment, which
could have lessened the substrate supply.
Corroborating the in vivo study, in vitro studies showed an anti-
proliferative effect of propionate on BaF3 cells. Therefore, we
suggest that propionate is, amongst the SCFA, the most likely
mediator of the ITF anti-tumour effect. We can speculate that
propionate uptake by the liver explains why ITF has an impact on
BaF3 cell progression in the liver and not in the spleen.
In human colon cancer cells and neutrophils, the anti-
proliferative capacity of SCFA has been associated with the SCFA
ability to inhibit histone deacetylase activity (Hinnebusch et al,
2002; Aoyama et al, 2010). Butyrate was the most powerful
inhibitor, whereas propionate demonstrated an intermediate
profile. Acetate did not influence the histone deacetylase activity
(Hinnebusch et al, 2002; Aoyama et al, 2010). In our in vitro
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experiments, both acetate and propionate reduce BaF3 cell
proliferation. This led us to hypothesise that targets other than
histone deacetylases might be involved in the in vitro anti-
proliferative effect of SCFA, namely FFA2 and FFA3. Quantitative
real-time PCR revealed that FFA3 expression in the BaF3 cells was
approximately 100-fold lower than FFA2 expression (data not
shown). Therefore, we focused on the potential implication of
FFA2. In view of the comparison of cell lines with different level of
expression of FFA2 (LLC and BaF3 cells), we postulate that FFA2
might be involved in the anti-proliferative action of propionate.
Free fatty acid receptor 2 can couple with the Gi and Gq pathways
(Brown et al, 2003; Le Poul et al, 2003). Blocking the Gq-PLC
pathway through a PLC inhibitor did not counteract the anti-
proliferative effect of propionate. Mimicking an increase in cAMP
level (by dibutyrylcAMP) and indirectly modifying cAMP level (by
IBMX or isoproterenol) significantly, but only slightly, reduces the
anti-proliferative effect of propionate. Therefore, we propose that
the anti-proliferative activity of propionate could be PLC-
independent and partially cAMP level-dependent. Phenylaceta-
mide derivatives, such as CMTB, have been recently described as
FFA2 agonists and are inactive against a panel of GPCRs (included
FFA3) at concentrations of up to 30 mM (Lee et al, 2008; Wang et al,
2010). Here, we establish that FFA2 activation by CMTB reduces
BaF3 cell growth through PLC- and cAMP level-dependent
pathways. Importantly, evidence from pharmacological studies
suggests that the signalling pathways downstream of FFA2 are
differentially activated by synthetic and endogenous ligands (Lee
et al, 2008). In fact, molecular modelling analysis revealed that
CMTB and endogenous ligands do not bind to the same site, and
this could be related to the fact that CMTB and propionate
differentially activate the Gi and Gq pathways. Indeed, CMTB
analogues equally activate Gq and Gi pathways, whereas propio-
nate is much more potent on the Gi than the Gq pathway (Lee et al,
2008). Additional work is needed to evaluate the molecular
characteristics of FFA2 at the protein level in FFA2-expressing
cancer cells, before really evaluating the contribution of the
binding of propionate to FFA2 in its anti-proliferative activity.
Finally, using human leukaemic cell lines, we have extended the
concept of FFA2 activation as a tumour-suppressive therapy. Tang
et al (2011b) recently reported that increasing the FFA2 expression
in human colon cancer cells by plasmid transfection sensitises
them to the action of propionate. Our results suggest that FFA2 is
of therapeutic interest for the treatment of different hematopoietic
cancers.
In conclusion, both in vivo and in vitro approaches support the
therapeutic potential of nutrients targeting the gut microbiota in
the control of leukaemic disease. We propose that propionate
production could be one of the gut microbial functions responsible
for the anti-tumour effect of prebiotic nutrients. Furthermore, our
data support the therapeutic interest in the pharmacological
activation of FFA2 to control cancer cell proliferation.
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